Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3131316 | 0.75 | DRD2 (0.34) | NISCHKDM4ELMNATDP1 | |
| SCHEMBL3074957 | 0.73 | ALOX5 (0.37) | NISCH | |
| SCHEMBL9729916 | 0.72 | TLK2 (0.31) | — | |
| SCHEMBL29244396 | 0.69 | NISCH (0.33) | NISCH | |
| SCHEMBL1456892 | 0.69 | HCAR2 (0.41) | LMNATDP1 | |
| SCHEMBL28143327 | 0.68 | NPC1 (0.36) | NISCHKDM4ELMNA | |
| SCHEMBL2446923 | 0.67 | KDM4E (0.43) | NISCHKDM4ELMNATDP1 | |
| SCHEMBL2596889 | 0.67 | ALDH1A1 (0.32) | LMNA | |
| SCHEMBL918364 | 0.67 | SCN4A (0.52) | LMNA | |
| Hydrochloric Acid SCHEMBL30014721 | 0.65 | SCN4A (0.50) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2522670-A1 | Heterocyclic CRF receptor antagonists | Takeda Pharmaceutical Company Limited (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7897607-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-01 | — | — | US | disclosed |
| EP-1732541-A4 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2008-03-05 | — | — | EP | disclosed |
| US-20070179165-A1 | Cyclic compounds | GYORKOS ALBERT C | 2007-08-02 | — | — | US | disclosed |
| EP-1732541-A2 | CYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005099688-A2 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-27 | — | — | WO | disclosed |
| US-5221742-A | PROCESS FOR THE PREPARATION OF 6-(3,4-DIHYDRO-3-OXO-1,4(2H)-BENZOXAZIN-7-YL)-2,3,4,5-TETRAHYDROPYRIDAZIN-3-ONES | ORTHO PHARMACEUTICAL CORPORATION (US) | 1993-06-22 | — | — | US | disclosed |
| WO-1992011256-A1 | PROCESS FOR THE PREPARATION OF BENZOXAZINYLTETRAHYDROPYRIDAZINES | ORTHO PHARMACEUTICAL CORPORATION (US) | 1992-07-09 | — | — | WO | disclosed |
| US-4721784-A | MUSCLE RELAXANTS, BRONCHODILATOR AGENTS, CARDIOTONIC AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179165-A1 | Cyclic compounds | CRHR1, CRHR2, MC2R | NISCH 3286/4885KDM4E 3537/4885LMNA 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.